🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

There are unique challenges the 18 million cancer survivors in the U.S. face, including side effects, financial toxicity, reduced quality of life, increased risk of new cancers, and psychosocial obstacles. Learn more in the AACR Cancer Progress Report. bit.ly/3S6eRZo

Review from my colleagues in NatureRevClinOncol on the less common variants of NSCLC. Key reminder that these diseases, like MET exon 14 or ALK+ lung cancer have similar incidence to some leukemias or lymphomas nature.com/articles/s4157… Alexander Drilon MD Guilherme Harada

For patients who develop #SCLC transformation after treatment with #osimertinib, Helena Yu discusses clinical outcomes with various treatments. #TTLC23 EGFR Resisters #EGFR #lungcancer #lcsm

Excellent presentation by Dr JessicaJLinMD about #ROS1 NSCLC resistance! IASLC #TTLC23

🚨TAGRISSO® (osimertinib) demonstrated strong overall survival benefit in the ADAURA Phase III trial for adjuvant treatment of patients with early-stage EGFR-mutated lung cancer - Earlier you start genomically targeted therapy the better they do 🧬🎯- this businesswire.com/news/home/2023…

FDA recommends that patients with dense breasts have a discussion with their doctor to ensure they receive information on the potential need for further evaluation or a repeat mammogram, the health regulator said. reuters.com/business/healt…

Department of Defense (DOD) Lung Cancer Research Program (LCRP) funding opportunities now accepting applications. Includes Career Development, Concept, Idea Development, & Translational Research Awards. LOIs due in May. See below for more details! CDMRP cdmrp.health.mil/funding/lcrp

Artificial intelligence-based model for lymph node metastases detection on whole slide images in bladder cancer: a retrospective, multicentre, diagnostic study The Lancet Oncology thelancet.com/journals/lanon…

Today our important study on air pollutants in the promotion of lung cancer has been published in nature led by Will Hill Emilia Lim Clare Weeden Swanton Lab ...Thread below🧵nature.com/articles/s4158…

Excited to share our TRACERx nature publication on circulating tumor DNA (#ctDNA, #MRD) detection in resectable lung cancer led by @AbboshChris, @Afrankell, Judit Kisistok, Thomas Harrison, Aaron Garnett, Nicolai Birkbak and Nicholas McGranahan 👇👇👇 Tweetorial🧵 nature.com/articles/s4158…

To understand tumour subclonal architecture in ctDNA we built ECLIPSE (github.com/amf71/ECLIPSE), a method which allows sensitive detection of subclones and estimation of subclone size (cancer cell fraction - CCF) from plasma containing ultra-low levels of ctDNA (down to 0.1%).

#cfDNA can capture clones across metastases to overcome sampling bias, but what about within the primary tumour? and how accurately? We found pre-surgery cfDNA could distinguish the tumour trunk from subclonal mutations masquerading as clonal in a single tissue biopsy (AUC 0.8)

Patients with >1 disseminating clone (polyclonal dissemination) had poor outcome, even after adjusting for clinical outcome predictors and disease burden, suggesting that the heterogeneity of the metastatic seeding population may drive adaptation and disease progression

#AACR23: For more on Beating #KRAS, don't miss this Cancer Discovery review - Expanding the Reach of Precision Oncology by Drugging All KRAS Mutants Marco Hofmann Daniel Gerlach Sandra Misale Norbert Kraut aacrjournals.org/cancerdiscover…

Great news! #ISLB has recently launched the 'Journal of Liquid Biopsy', the first open-access publication focused on #liquidbiopsy. We are thrilled to also announce Prof. Umberto Malapelle as Editor-in-Chief. More at islb.info/journal-of-liq… Oncology Advance OncoAlert

Touching piece Journal of Clinical Oncology: "At a Loss: Patient Deaths and Clinical Research Coordinators" reminds us of the impact of a patient's death on research coordinators who are often left with a "disenfranchised form of grief", often devastating but unacknowledged. ascopubs.org/doi/full/10.12…

We’re initiating a real-world study to evaluate the clinical impact of #MCED screening among Medicare beneficiaries. Learn more here: bit.ly/47IVxrB Please see enclosed video providing a study overview: bit.ly/47FLRhB

Update: GRAIL is set to initiate the REACH Study, evaluating the clinical impact of Galleri® MCED Test among the Medicare population. 🌐 Dr. Clunie emphasized the NMA's commitment to health equity & eliminating disparities in healthcare. Read more here: bit.ly/3R8cbLY

What is the role of the TME in lung cancer evolution? We are excited to share our new TRACERx paper “Spatial Architecture of Myeloid and T Cells Orchestrates Immune Evasion and Clinical Outcome in Lung Cancer” at #AACR24, out in Cancer Discovery today rb.gy/q484j9 Tweetorial👇

Using the #NationalCancerPlan to drive innovation in cancer research #Every1HasARole #AACR24 Dr. Kimryn Rathmell nationalcancerplan.cancer.gov/national-cance… #HealthEquity #DataSharing #CancerPrevention #MCD